Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 3Withdrawn 1

Sponsor Class

OTHER 4

Study Type

Observational 3Interventional 1

Sponsor

Cancer Type

Gastrointestinal 10Other hematologic neoplasm 9Sarcoma 5Lymphoid 5Thoracic 4Gynecologic 4Genitourinary 4Breast 4Other solid neoplasm 2Head & Neck 2Dermatologic 2Tumor-Agnostic 1Myeloid 1Endocrine 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2

Interventions

Trastuzumab 728Paclitaxel 694Cyclophosphamide 647Docetaxel 559Capecitabine 485Letrozole 437Fulvestrant 398Carboplatin 397Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 272exemestane 258Epirubicin 251Radiotherapy 239pertuzumab 237palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 151Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Base Sequence × Breast × Clear all
NCT05652569 2026-01-28

CATCH

German Cancer Research Center

Recruiting
5,000 enrolled
Breast

Breast Neoplasms

NCT05906407 2025-03-19

COGNITION

German Cancer Research Center

Recruiting
2,000 enrolled
Breast

Breast Neoplasms

NCT05916755 2023-06-23

PORTRAIT

Vall d'Hebron Institute of Oncology

Recruiting
100 enrolled
Breast

Triple Negative Breast Neoplasms

NCT01292083 2014-02-06

Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery

University of Southern California

Phase NA Withdrawn
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡